STOCK TITAN

Erasca: 44% response in ERAS-0015 pancreatic cancer cohort

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Erasca, Inc. reported interim Phase 1 results for ERAS-0015. At the September 1, 2026 cutoff, confirmed ORR was 44% in 25 KRAS G12X PDAC patients at 32 mg once daily in second line or later, and 69% in 13 patients with KRAS G12D or G12V PDAC. Confirmed ORR was 58% in 12 KRAS G12X NSCLC patients across 16–32 mg and 75% in four biliary tract cancer patients at 32 mg.

At 32 mg, TRAEs caused dose interruptions in 13.0% and reductions in 16.7% of 54 patients, with no discontinuations. One previously reported pneumonitis TRAE progressed from Grade 3 to Grade 5 after the patient requested withdrawal of supportive care; no further Grade 5 TRAEs occurred. Combination escalation showed multiple responses with pembrolizumab and panitumumab; gemcitabine/nab-paclitaxel efficacy data were not yet available. Preliminary ERAS-4001 data showed no TRAEs leading to discontinuation.

First-line PDAC Phase 3 and potentially registration-enabling second-line-or-later RAS-mutant NSCLC trials are expected to start in the first half of 2027. First-line RAS-mutant NSCLC Phase 3 is expected in the second half of 2027 to the first half of 2028; an ERAS-0015/ERAS-4001 combination dose-escalation trial is planned for 2027.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Minor pointERAS-0015: 44% confirmed ORR in 25 KRAS G12X PDAC patients at 32 mg.

Negative

  • Moderate pointOne pneumonitis TRAE progressed to Grade 5 after the patient requested withdrawal of supportive care.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Confirmed ORR 44% (25 patients) KRAS G12X PDAC, 32 mg once daily, second line or later
Confirmed ORR 69% (13 patients) KRAS G12D or G12V PDAC
Confirmed ORR 58% (12 patients) KRAS G12X NSCLC, across 16–32 mg
Confirmed ORR 75% (4 patients) Biliary tract cancer at 32 mg
Dose interruptions due to TRAEs 13.0% (7 of 54 patients) ERAS-0015 at 32 mg
Dose reductions due to TRAEs 16.7% (9 of 54 patients) ERAS-0015 at 32 mg
Grade 5 TRAEs 1 event Previously reported pneumonitis event that progressed from Grade 3 to Grade 5
Phase 3 trial initiation First half of 2027 First-line PDAC and potentially registration-enabling second-line-or-later RAS-mutant NSCLC trials
objective response rate medical
"confirmed objective response rate (“ORR”)"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
pharmacologically active doses medical
"pharmacologically active doses (“PAD”) of 16-32 mg"
dose-limiting toxicities medical
"no dose-limiting toxicities (“DLTs”)"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
relative dose intensity medical
"100% median relative dose intensity (RDI)"
Relative dose intensity (RDI) is the amount of a drug a patient actually receives over a specified time compared with the planned or standard amount for that same time, expressed as a percentage. It is calculated by dividing the delivered dose intensity (total dose divided by treatment duration) by the planned dose intensity and multiplying by 100; reductions in dose or treatment delays lower the RDI, and the metric is specific to the regimen and time period being measured.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What response rate did ERAS-0015 show in pancreatic cancer?

Confirmed ORR was 44% in 25 KRAS G12X PDAC patients at 32 mg once daily in second line or later. The confirmed ORR was 69% among 13 patients with KRAS G12D or G12V PDAC.

When are Erasca's planned ERAS-0015 trials expected to start?

The first-line PDAC Phase 3 and potentially registration-enabling second-line-or-later RAS-mutant NSCLC trials are expected to start in the first half of 2027. The first-line RAS-mutant NSCLC Phase 3 is expected in the second half of 2027 to the first half of 2028.

What did Erasca report about ERAS-0015 combination trials?

The gemcitabine and nab-paclitaxel combination cleared the dose-limiting toxicity window through 16 mg with no dose-limiting toxicities; the 24 mg dose-escalation cohort was dosing. Multiple responses were observed with pembrolizumab. With panitumumab, two patients treated at 24 mg and then dose-reduced to 16 mg had ongoing confirmed partial responses.

What response rates did ERAS-0015 show in NSCLC and biliary tract cancer?

Confirmed ORR was 58% in 12 KRAS G12X NSCLC patients across the 16–32 mg range, in second- or third-line treatment after immune checkpoint inhibitor and platinum-based chemotherapy. It was 75% in four biliary tract cancer patients at 32 mg in first line or later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000176191800017619182026-11-202026-11-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2026

 

 

Erasca, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40602

83-1217027

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3115 Merryfield Row

Suite 300

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 465-6511

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

ERAS

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 8.01 Other Events.

On November 20, 2026, Erasca, Inc. (the “Company”) announced updated U.S. Phase 1 monotherapy and initial combination data reinforcing the best-in-class potential of pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. The Company is accelerating the planned initiation of a Phase 3 trial in first-line (“1L”) pancreatic cancer to the first half of 2027. The Company also announced encouraging initial U.S. Phase 1 monotherapy data for potential first-in-class pan-KRAS inhibitor ERAS-4001, supporting its combination potential with ERAS-0015.

 

Key U.S. Phase 1 interim results for ERAS-0015 (AURORAS-1):

As of the data cutoff date, ERAS-0015 monotherapy at the pharmacologically active doses (“PAD”) of 16-32 mg once daily (“QD”) (N=122) was generally well-tolerated with favorable safety data, and demonstrated encouraging activity in key KRAS G12X tumors. Monotherapy responses shown are confirmed. All patients with responses at 32 mg QD in all tumor types remained on treatment.1,2

ERAS-0015 Monotherapy Showed Strong Anti-Tumor Activity Across Advanced KRAS-Mutant Cancers

•
KRAS G12X pancreatic ductal adenocarcinoma (“PDAC”) at 32 mg QD in the second-line or greater (“2L+”) setting1,2
o
44% confirmed objective response rate (“ORR”) across all patients (N=25) with KRAS G12X mutations; 84% were treated in the third-line or later (“3L+”) setting and 44% had G12R mutations
o
69% confirmed ORR in patients (N=13) with KRAS G12D or G12V PDAC, which represent nearly 70% of patients with PDAC. Of these patients, 77% were treated in 3L+
•
63% confirmed ORR (N=8) in patients with KRAS G12D
•
80% confirmed ORR (N=5) in patients with KRAS G12V
o
All (11 of 11) patients with confirmed responses and 6 of 11 patients with stable disease remained on treatment
•
KRAS G12X non-small cell lung cancer (“NSCLC”)1,2
o
60% confirmed ORR (N=5) at 32 mg QD and 58% confirmed ORR (N=12) across the PAD range of 16-32 mg QD in the second line (“2L”) or third line (“3L”) setting following an immune checkpoint inhibitor and platinum-based chemotherapy (post-ICI/platinum)
o
Activity was observed across multiple KRAS mutation subtypes at 32 mg QD in the 2L+ setting:
•
60% confirmed ORR (N=5) in patients with KRAS G12D mutations
•
50% confirmed ORR (N=4) in patients with KRAS G12V mutations
o
At 32 mg QD in the 2L+ setting, all (5 of 5) patients with confirmed responses and all (5 of 5) patients with stable disease remained on treatment
•
KRAS G12X biliary tract cancer (“BTC”) at 32 mg QD in the first line or greater (“1L+”) setting1
o
75% confirmed ORR (N=4)
o
All (3 of 3) patients with confirmed responses remained on treatment

 

 

ERAS-0015 Monotherapy Continued to Be Generally Well-Tolerated with Favorable Safety Data in Expanded Patient Population1

•
Frequency and severity of treatment-related adverse events (“TRAEs”) remained consistent with the Company’s April and July 2026 interim data disclosures

•
Mostly low-grade TRAEs with no dose-limiting toxicities (“DLTs”) and low rate of dose interruptions, reductions, and discontinuations due to TRAEs
o
At 32 mg QD (N=54), TRAEs led to dose interruptions in 13.0% of patients and dose reductions in 16.7% of patients, and there were no dose discontinuations (0% of patients)
•
100% median relative dose intensity (RDI) at 32 mg QD

 

Early ERAS-0015 Combination Data Support Further Development and Potential for Differentiation with Standard-of-Care Therapies3

•
ERAS-0015 plus gemcitabine + nab-paclitaxel (Days 1 and 15):
o
Generally well tolerated with favorable safety data and no unexpected safety signals
o
The DLT window was cleared through the 16 mg QD ERAS-0015 cohort with no DLTs
o
Currently dosing the 24 mg QD ERAS-0015 dose escalation cohort
o
Efficacy data not yet available
o
Clinical data support further development in 1L PDAC

 

•
ERAS-0015 plus pembrolizumab:
o
Generally well tolerated with favorable safety data and no unexpected safety signals
o
The DLT window was cleared through the 32 mg QD ERAS-0015 cohort with no DLTs
o
Multiple responses observed in multiple solid tumor types in dose escalation
o
Clinical data support further development in 1L NSCLC, including combination with carboplatin/pemetrexed/pembrolizumab (initiated in Q4)

 

•
ERAS-0015 plus panitumumab:
o
16 mg QD ERAS-0015 was generally well tolerated with favorable safety data and no unexpected safety signals
o
Multiple responses were observed in dose escalation in patients with KRAS G12X colorectal cancer (“CRC”), including 2 ongoing confirmed partial responses (“PR”) in 2 patients treated at 24 mg QD who then dose reduced to 16 mg QD, and 1 unconfirmed PR (“uPR”) in 4 patients treated at 16 mg QD
o
Combination dose exploration ongoing; plan to make dose selection in 2027

 

Encouraging Preliminary ERAS-4001 Phase 1 Data Support Planned Combination with ERAS-00154

•
Favorable safety and tolerability data with predominantly low-grade adverse events and no TRAEs leading to treatment discontinuation
•
Pharmacokinetic (“PK”) results were encouraging and support continued dose escalation
•
Preliminary monotherapy antitumor activity supports ERAS-4001’s potential as a combination partner for ERAS-0015
•
Nonclinical data demonstrated that the combination of ERAS-0015 and ERAS-4001 targets both active- and inactive-state KRAS and exhibits synergistic activity in KRAS G12X-driven models, providing a rationale for further evaluation of this combination

 

¹ Data cutoff date (“DCO”) September 1, 2026
² Includes responses confirmed after the data cutoff date
3 DCO October 14, 2026
4 As of November 9, 2026


Additional AURORAS-1 Safety Data

The following table summarizes all TRAEs occurring in 10% or more of patients in the AURORAS-1 trial as of the September 1, 2026 DCO date:

 

Summary of TRAEs occurring in ≥10% of patients

All Patients Treated at PAD (16-32 mg QD; N=122) and 32 mg QD (N=54) of ERAS-0015

 

16-32 mg QD (N=122)

32 mg QD (N=54)

TRAEs, n (%)

Grade 1

Grade 2

Grade 32

Grade 4

Grade 5

All Grades

All Grades

Rash1, n (%)

61 (50.0)

34 (27.9)

4 (3.3)

0

0

99 (81.1)

43 (79.6)

Diarrhea, n (%)

30 (24.6)

8 (6.6)

1 (0.8)

0

0

39 (32.0)

19 (35.2)

Nausea, n (%)

22 (18.0)

7 (5.7)

0

0

0

29 (23.8)

12 (22.2)

Stomatitis, n (%)

15 (12.3)

8 (6.6)

3 (2.5)

0

0

26 (21.3)

14 (25.9)

TRAEs leading to dose interruptions, n (%)

 

 

 

 

 

15 (12.3)

7 (13.0)

TRAEs leading to dose reductions, n (%)

 

 

 

 

 

13 (10.7)

9 (16.7)

TRAEs leading to dose discontinuations, n (%)

 

 

 

 

 

2 (1.6)

0

No prophylaxis recommended in the protocol. Safety set includes all patients that have received at least one dose of ERAS-0015.

 

¹ Rash events are identified using following preferred term rash pustular, rash papular, rash maculo-papular, rash macular, rash, erythema and dermatitis acneiform (uncoded terms rash acneiform and rash, are also included).

2 As disclosed by the Company in April 2026, one Grade 3 TRAE of pneumonitis progressed to Grade 5 after withdrawal of supportive care per patient decision. The patient was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma who received 24 mg of ERAS-0015. The patient had pulmonary metastases, a history of right lung cryoablation and no history of lung radiation. The patient presented to the ER approximately a month after starting ERAS-0015 with Grade 3 pneumonitis that was treated aggressively with immediate discontinuation of ERAS-0015, high dose steroids and infliximab. The patient requested withdrawal of supportive care and ultimately died of the event. No additional Grade 5 TRAEs have occurred.

 

RAS-Mutant BTC: Opportunity to Address Unmet Need

RAS mutations occur in approximately 17% of patients with BTC. The Company estimates that approximately 5,000 patients in the United States and approximately 45,000 patients outside the United States are diagnosed with RAS-mutant BTC each year. Five-year survival for patients with distant-stage BTC is approximately 2–4%. In the first-line setting, the standard-of-care regimen of pembrolizumab plus gemcitabine and cisplatin achieved an ORR of 29% in BTC overall.


 

Key Anticipated Milestones

ERAS-0015: AURORAS-1 and Phase 3 Trials

•
Potentially registration-enabling trial in patients with 2L+ RAS-mutant NSCLC expected to initiate in the first half of 2027
•
Phase 3 trial in patients with 1L PDAC accelerated to initiate in the first half of 2027
•
Phase 3 trial in patients with 1L RAS-mutant NSCLC expected to initiate in the second half of 2027 to the first half of 2028
•
Combination dose escalation and expansion data expected in 2027

ERAS-4001: BOREALIS-1 Trial

•
Initiation of combination dose escalation trial with ERAS-0015 planned for 2027

 

Cautionary Note Regarding Forward-Looking Statements

The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to: its expectations regarding the potential therapeutic benefits for each of its product candidates, including ERAS-0015 and ERAS-4001; the planned advancement of its development pipeline, including the anticipated timing of data readouts for the AURORAS-1 and BOREALIS-1 trials, and its expectations related to the initiation of its clinical trials and patient cohorts; its plans to initiate multiple potentially registration-enabling trials for ERAS-0015 in lung cancer and pancreatic cancer in the time periods set forth in this report; characterizations of the clinical profile of ERAS-0015 and ERAS-4001; the potential for ERAS-0015 to be used in combination therapies, including in combination with ERAS-4001; the potential for ERAS-0015 to be best-in-class; and the potential for ERAS-4001 to be first-in-class and best-in-class. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation: potential delays in the initiation, enrollment, data readout, and completion of clinical trials, including the AURORAS-1 and BOREALIS-1 trials and the planned future trials discussed in this report; the Company’s product candidates, including ERAS-0015 and ERAS-4001, may not demonstrate therapeutic benefits that it expects; interim, topline and preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that an unconfirmed partial response to treatment may not ultimately result in a confirmed partial response to treatment after follow-up evaluations; the limitations of preliminary data based on small patient populations and limited follow-up, and of cross-study comparisons that are not based on head-to-head trials and may not be directly comparable due to differences in study designs, patient populations and assessment methods; fast track designation may not result in a more expedited development or regulatory review process, and such a designation does not increase the likelihood that ERAS-0015 will receive marketing approval in the United States; the Company’s approach to the discovery and development of product candidates is based on its singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; results from preclinical studies not necessarily being predictive of future results; the Company’s assumptions around which programs may have a higher probability of success may not be accurate, and it may expend its limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; the Company’s dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of the Company’s product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; the Company’s planned potentially registration-enabling trials may be delayed based on U.S. Food and Drug Administration (“FDA”) feedback or requirements, as the FDA retains broad discretion to require additional clinical data prior to the conduct of a registrational trial or submission for regulatory approval; even if the Company’s planned trials are successful, they may not support regulatory approval; the inability to realize any


benefits from the Company’s current licenses, acquisitions, and collaborations, and any future licenses, acquisitions, or collaborations, and the Company’s ability to fulfill its obligations under such arrangements; regulatory developments in the United States and foreign countries; the Company’s ability to obtain and maintain intellectual property protection for its product candidates and maintain its rights under intellectual property licenses, including its ability to successfully defend against allegations raised by, or any future litigation initiated by, Revolution Medicines (“RevMed”) that ERAS-0015 infringes patents held by RevMed or was derived from RevMed trade secrets; the sufficiency of the Company’s cash, cash equivalents, and marketable securities; the Company may use its capital resources sooner than it expects; and other risks described in the Company’s prior filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Erasca, Inc.

 

 

 

 

Date:

November 20, 2026

By:

/s/ Ebun Garner

 

 

 

Chief Legal Officer

 


Filing Exhibits & Attachments

1 document

Keep reading